Serum anti-laminarin antibodies in colorectal cancer: a prospective pilot study

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11150%2F21%3A10440274" target="_blank" >RIV/00216208:11150/21:10440274 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00179906:_____/21:10440274

Výsledek na webu

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=6R1.ScylSE" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=6R1.ScylSE</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.48095/ccgh2021323" target="_blank" >10.48095/ccgh2021323</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Serum anti-laminarin antibodies in colorectal cancer: a prospective pilot study

Popis výsledku v původním jazyce

Laminarin is a low molecular weight (504 Da) glucose branched polysaccharide which modulates humoral and cellular immune response, both non-specific and specific. Laminarin possesses anti-tumorous activity as it induces apoptosis and modulates the colonic microbio-ta. The aim of our current study was to evaluate anti-laminarin antibodies in colorectal carcinoma. Methods: A total of 46 individuals were enrolled in the prospective study including 14 controls (5 men, 9 women, age 29-80, mean 55 +- 13) and 32 patients with colorectal carcinoma, CRC (14 men, 18 women, age 46-86, mean 66 +- 11). Two outliers were identified in the CRC group. Out of 30 CRC patients, 12 individuals had right-sided CRC (12/30; 40%). Majority of the CRC patients had stage III (13/30; 43%) or IV (13/30; 43%) cancer. Most of the CRC patients had moderately (15/30; 50%) or poorly (11/30; 37%) differentiated CRC. Samples were obtained from the peripheral venous blood and investigation of the serum IgG anti-laminarin antibodies was performed by means of ELISA and measured in U/mL. Results: Serum anti-laminarin antibodies were significantly higher in controls compared to the CRC group (16.23 +- 6.60; 11.41 +- 5.53; p = 0.015) and in controls compared to left-sided carcinoma (11.38 +- 5.39; p = 0.046). A statistically significant difference was observed between controls and CRC stage III (11.01 +- 3.36; p = 0.017) and between controls and CRC stage IV (10.98 +- 6.06; p = 0.049). Anti-laminarin antibodies were significantly lower in moderately differentiated CRC compared to controls (10.78 +- 5.22; p = 0.020), but not in poorly differentiated CRC (12.10 +- 6.28; p = 0.755). No difference was identified between controls and females with CRC (11.94 +- 6.39; p = 0.092). There was a significant difference between controls and males with CRC (10.72 +- 4.32; p = 0.017). Conclusion: Serum anti-laminarin antibodies were significantly lower in the CRC group and CRC subgroups compared to controls.

Název v anglickém jazyce

Serum anti-laminarin antibodies in colorectal cancer: a prospective pilot study

Popis výsledku anglicky

Laminarin is a low molecular weight (504 Da) glucose branched polysaccharide which modulates humoral and cellular immune response, both non-specific and specific. Laminarin possesses anti-tumorous activity as it induces apoptosis and modulates the colonic microbio-ta. The aim of our current study was to evaluate anti-laminarin antibodies in colorectal carcinoma. Methods: A total of 46 individuals were enrolled in the prospective study including 14 controls (5 men, 9 women, age 29-80, mean 55 +- 13) and 32 patients with colorectal carcinoma, CRC (14 men, 18 women, age 46-86, mean 66 +- 11). Two outliers were identified in the CRC group. Out of 30 CRC patients, 12 individuals had right-sided CRC (12/30; 40%). Majority of the CRC patients had stage III (13/30; 43%) or IV (13/30; 43%) cancer. Most of the CRC patients had moderately (15/30; 50%) or poorly (11/30; 37%) differentiated CRC. Samples were obtained from the peripheral venous blood and investigation of the serum IgG anti-laminarin antibodies was performed by means of ELISA and measured in U/mL. Results: Serum anti-laminarin antibodies were significantly higher in controls compared to the CRC group (16.23 +- 6.60; 11.41 +- 5.53; p = 0.015) and in controls compared to left-sided carcinoma (11.38 +- 5.39; p = 0.046). A statistically significant difference was observed between controls and CRC stage III (11.01 +- 3.36; p = 0.017) and between controls and CRC stage IV (10.98 +- 6.06; p = 0.049). Anti-laminarin antibodies were significantly lower in moderately differentiated CRC compared to controls (10.78 +- 5.22; p = 0.020), but not in poorly differentiated CRC (12.10 +- 6.28; p = 0.755). No difference was identified between controls and females with CRC (11.94 +- 6.39; p = 0.092). There was a significant difference between controls and males with CRC (10.72 +- 4.32; p = 0.017). Conclusion: Serum anti-laminarin antibodies were significantly lower in the CRC group and CRC subgroups compared to controls.

Druh

J_SC - Článek v periodiku v databázi SCOPUS

CEP obor

—

OECD FORD obor

30219 - Gastroenterology and hepatology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2021

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Gastroenterologie a hepatologie

ISSN

1804-7874

e-ISSN

—

Svazek periodika

75

Číslo periodika v rámci svazku

4

Stát vydavatele periodika

CZ - Česká republika

Počet stran výsledku

5

Strana od-do

323-327

Kód UT WoS článku

—

EID výsledku v databázi Scopus

2-s2.0-85113543922